Arbutus Biopharma Corp (ABUS) — Cash Flow-to-Debt Ratio
Arbutus Biopharma Corp (ABUS) has a Cash Flow-to-Debt Ratio of -0.48x as of March 2026, meaning its operating cash flow of $-8.11 Million could theoretically repay 0% of its total liabilities ($16.99 Million) in one year. See Arbutus Biopharma Corp (ABUS) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Arbutus Biopharma Corp Cash Flow-to-Debt Ratio (1998–2025)
Historical debt coverage capacity for Arbutus Biopharma Corp across 28 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Arbutus Biopharma Corp.
Annual Cash Flow-to-Debt Ratio for Arbutus Biopharma Corp (1998–2025)
Year-by-year debt coverage analysis for Arbutus Biopharma Corp. Check earnings quality score of Arbutus Biopharma Corp to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.20x | $-39.64 Million | $18.04 Million | ▼ -16.3% |
| 2024 | -1.89x | $-64.85 Million | $34.34 Million | ▲ +15.7% |
| 2023 | -2.24x | $-85.94 Million | $38.38 Million | ▼ -270.9% |
| 2022 | -0.60x | $-35.36 Million | $58.57 Million | ▲ +68.7% |
| 2021 | -1.93x | $-67.53 Million | $35.05 Million | ▼ -31.5% |
| 2020 | -1.46x | $-51.44 Million | $35.11 Million | ▲ +32.3% |
| 2019 | -2.17x | $-71.01 Million | $32.79 Million | ▲ +11.8% |
| 2018 | -2.45x | $-67.90 Million | $27.67 Million | ▼ -176.2% |
| 2017 | -0.89x | $-48.60 Million | $54.70 Million | ▼ -11.9% |
| 2016 | -0.79x | $-57.88 Million | $72.90 Million | ▼ -138.6% |
| 2015 | -0.33x | $-54.78 Million | $164.61 Million | ▲ +19.1% |
| 2014 | -0.41x | $-12.42 Million | $30.20 Million | ▲ +23.6% |
| 2013 | -0.54x | $-6.74 Million | $12.52 Million | ▼ -118.9% |
| 2012 | 2.85x | $33.27 Million | $11.68 Million | ▲ +421.9% |
| 2011 | -0.89x | $-7.52 Million | $8.50 Million | ▲ +19.0% |
| 2010 | -1.09x | $-11.25 Million | $10.29 Million | ▼ -35.8% |
| 2009 | -0.80x | $-5.24 Million | $6.51 Million | ▲ +61.6% |
| 2008 | -2.09x | $-8.48 Million | $4.05 Million | ▼ -397.5% |
| 2007 | -0.42x | $-2.72 Million | $6.46 Million | ▲ +5.7% |
| 2006 | -0.45x | $-2.62 Million | $5.88 Million | ▼ -13.2% |
| 2005 | -0.39x | $-14.57 Million | $36.99 Million | ▼ -103.6% |
| 2004 | -0.19x | $-9.98 Million | $51.60 Million | ▲ +94.7% |
| 2003 | -3.67x | $-26.96 Million | $7.35 Million | ▼ -59.0% |
| 2002 | -2.31x | $-18.16 Million | $7.87 Million | ▼ -41.1% |
| 2001 | -1.64x | $-10.00 Million | $6.12 Million | ▲ +51.2% |
| 2000 | -3.35x | $-8.35 Million | $2.49 Million | ▲ +5.9% |
| 1999 | -3.56x | $-6.84 Million | $1.92 Million | ▲ +35.1% |
| 1998 | -5.49x | $-7.71 Million | $1.40 Million | — |